Bangladesh is one of the countries facing huge burden of hepatocellular carcinoma (HCC). Hepatocellular carcinoma is the third commonest cancer in the country and it is just behind to cancer of the lung and cancer of the stomach. Hepatitis B virus (HBV) is responsible for 66% of HCC in Bangladesh. Presumptive prevalence of HBV and hepatitis C virus (HCV) may be as high as 5.4 and 0.84%, respectively, in Bangladesh, and liver diseases occupied 8 to 12% of admission in medicine wards of Public Medical College. In this mini review, I would like to highlight the impact of HBV and HCV in the development of HCC and the management of HCC from a Bangladesh perspective.
INTRODUCTION
The whole world is facing the burden of cancer and Bangladesh is not out of the scene. Hepatocellular carcinoma is the sixth most common malignancy in the whole world and is responsible for 7% of all malignancy. Hepatitis B virus is mainly responsible for chronic hepatitis and HCC in our country. After introduction of HBV vaccine in expanded program on immunization (EPI), prevalence of HBV is progressively decreasing. By the year 2030, practical elimination of HBV from Bangladesh is our target.
HEPATITIS B
The prevalence of HBV in Bangladesh is 5.4%. In this HBV intermediate prevalence zone, liver disease accounts for 8 to 12% of hospital admission in private medical college medicine wards. This is a huge burden for the health system in our country. The HBV vaccine is incorporated in EPI in 2003, and EPI had 93% coverage by 2010. 
NASVAC
In the recent field of HBV treatment, hepatitis B core antigen-based vaccine is a great innovation in Bangladesh. Nasal vaccine containing recombinant HBV surface and core antigens already passed phases I, II, and III clinical trials conducted in Bangladesh. NASVAC was administered in 75 patients every 2 weekly intranasally at a dose of 100 µg for five times followed by every 2 weekly administration of 100 µg intranasally plus 100 µg subcutaneously. Seventy-six patients received injection Pegylated interferon alpha-2b at a dose of 180 µg for 53 EJOHG 48 weeks. NASVAC safety was very satisfactory. At 48 weeks of end of treatment, alanine transaminase was 77% of upper limit of normal, HBeAg seroconversion was 33.3%. Most encouraging is fibrosis was regressed and >18.0 kPa was not found in any patients receiving NASVAC. NASVAC has been licensed as drug in Cuba, Nigeria, and Angola. Phase I clinical trial is going on in Japan also.
ANTI-HCC THERAPY
Different regimes are used in HCC management, such as liver transplantation, surgical excision, local ablation [radiofrequency ablation, percutaneous ethanol injection (PEI)], anticancer drugs (sorafenib), transarterial chemoembolization (TACE), combination therapy (TACE + sorafenib). All therapies target reduction of HCC and prolongation of life. But no therapy targets pathogenesis of HCC.
SCOPE OF IMMUNE THERAPY IN HCC
In HCC, there is decreased immune response as cancer cells are regarded as self, immune evasion by cancer cells, mutations bypass host immunity, and problem in migration of immunocytes in cancer nodules, host remain immune compromised, proper antigen is not recognized, immunocytes cannot act appropriately. New approach introduces PEI plus dendritic cells (DC) therapy, which helps in recognition of HCC antigen from cancer nodule, converting HCC antigens to danger signal for appropriate immune response. The PEI plus DC therapy reduces tumor size and improves survival in mice model. Tumor marker also declined progressively in treated HCC patients.
Bangladesh Medical and Research Council had given the ethical clearance, and the first case is expected in November 2017.
CONCLUSION
Bangladesh is facing huge burden of liver disease patients as it is in HBV intermediate zone. After incorporating HBV vaccine in EPI, situation is changing. Trial of new drug innovation is going on in Bangladesh. Our target is free HBV Bangladesh by 2030 and free HBV HCC also.
